Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant axitinib + avelumab for localized renal cell carcinoma at moderate to high risk of recurrence
NL-OMON48706Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib and avelumab in renal cell carcinoma (RCC) and kidney cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Rate of partial remission. Started Jun 2018; status: recruiting.
02
Drugs
axitinibavelumab
03
Conditions
renal cell carcinoma (RCC)kidney cancer
Beyond the preview
Go deeper on NL-OMON48706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48706.